Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: Are they clinically relevant?

Drug Safety

Volumn 26, Issue 1, 2003, Pages 13-21

  Martin, Jennifer ^a   Krum, Henry ^b  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; FLUOXETINE; FLUVOXAMINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NELFINAVIR; PRAVASTATIN; ROSUVASTATIN; SERTRALINE; SIMVASTATIN;

CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; GRAPEFRUIT JUICE; HUMAN; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 0037229225     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326010-00002     Document Type: Review

References (48)

1. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme a reductase inhibitors. Arch Intern Med 2000; 160: 2273-80
2. McCormick AD, Butters CJ. ZD4522: an HMG-CoA reductase inhibitor free of metabolically medicated drug interactions: metabolic studies in human in vitro systems. 29th Annual Meeting of the American College of Clinical Pharmacology; 2000 Sep 17-19; Chicago (IL), 2002
3. Azie N, Brater BC, Becker P, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64 (4): 369-77
4. Yeo KR. Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51 (5): 461-70
5. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64 (2): 177-82
6. Kantola T, Neuvonen P. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 1998; 64: 58-65
7. Neuvonen P, Kantola T, Kivisto K. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63 (3): 332-41
8. Kivisto K, Kantola T, Neuvonen P. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53
9. Kantola T, Neuvonen P. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 387-402
10. Lilja J, Neuvonen P. Grapefruit juice - simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-83
11. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibafredil. Lancet 1998; 351: 1929-30
12. Kent J. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2001; 355 (9207): 911-8
13. Martin J, Fay M. Cytochrome P450 drug interactions: are they clinically relevant? Australian Prescriber 2001; 24 (1): 10-2
14. Davidson M. Statin drug interactions in the elderly. J Cardiovasc Pharmacol Ther 2001; 6 (3): 219-29
15. Sugimoto K, Ohmori M, Tsuruka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70 (6): 518-24
16. Hsyu P-H, Schultz-Smith M, Lillibrisge J, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45 (12): 3445-50
17. Ruschitzka F, Meier P, Turina M, et al. Acute heart transplant rejection due to Saint John's wort [letter]. Lancet 2000; 35 (9203): 548-9
18. Lees R. Rhabdomyolysis from the co-administration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 644-5
19. Beaird S. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc 2000; 40: 637-44
20. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol 1996; 132: 1254-5
21. Ahmad S. Diltiazem myopathy. Am Heart J 1993; 126: 1494-5
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
23. Rodriguez JA, Paniagua MJ, Crespo-Leiro MG, et al. Rhabdomyolysis with HMG Co-A reductase inhibitors after heart transplant: incidence and prognosis [poster]. Presented at the European Society of Cardiology Congress; 1998 Aug 22-26; Vienna
24. Keogh A, Macdonald P, Aboyoun C, et al. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000; 19: 529-37
25. Barclay P, O'Connell P. Clarithromycin drug interactions complicating cyclosporin and simvastatin therapy [letter]. Aust J Hosp Pharm 1996; 26: 180
26. Corpier C, Jones P, Suki W, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. J Am Med Assoc 1988; 260 (2): 239-41
27. Maltz H, Balog D, Cheigh J. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-9
28. Muck W, Mai I, Fritsche L, et al. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin Pharmacol Ther 1999; 65: 251-61
29. Regazzi M, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc 1993; 25: 2732-4
30. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin but not pravastatin in blood of cyclsporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62: 311-21
31. Goldberg R, Roth O. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporirie. Transplantation 1996; 62: 1559-64
32. Gruer P, Vega J, Mercuri M, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-5
33. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atherosclerosis 2002; Suppl. 3: 35-40
34. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of the 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34
35. Spach D, Clark C, Burke W. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213-5
36. Ayanian J, Fuchs C, Stone R. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1998; 1009: 682-3
37. Heerey A, Barry M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169 (3): 176-9
38. Jacobson R, Wang P, Glueck C. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone [letter]. JAMA 1997; 277: 296-7
39. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998 Nov 5; 339 (19): 1349-57
40. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 Nov 16; 333 (20): 1301-7
41. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335 (14): 1001-9
42. Pfeffer M, Keech A, Cobbe S, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) project. Circulation 2002; 105: 2341-6
43. Furberg C Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiavasc Med 2001; 2: 205-7
44. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 356-64
45. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22 (6): 441-57
46. Wen X, Wang J, Backman J, et al. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001; 29: 1359-61
47. Prueksaritanont T, Zhao J, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-51
48. Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13-20